Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Median Techno    ALMDT   FR0011049824

SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets 

MEDIANTECHNOLOGIES : MEDIAN Technologies Joins Forces with Quintiles to Provide World-Class Clinical Trial Imaging Services

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/16/2012 | 06:35pm CEST

Regulatory News:

Strategic agreement to leverage MEDIAN's advanced lesion management system (LMS) software applications and associated clinical trial imaging services for early, late-stage or post-approval oncology clinical trials

To improve the assessment of how cancer patients are responding to investigational therapies in clinical trials, MEDIAN Technologies (Paris:ALMDT) today announced a strategic agreement with Quintiles to offer advanced integrated image services to biopharmaceutical customers worldwide.

The agreement with Median, a leading services provider for image interpretation and management in oncology clinical trials, is designed to further strengthen Quintiles' full range of services to accelerate oncology drug development. With Quintiles, the world's leading biopharmaceutical services provider, as its partner, Median can extend the reach of its technologies in the clinical development field to benefit customers globally.

"This collaboration will result in better quality of data, increased awareness for biopharma for go/no-go decisions along the drug development stages, and ultimately more robust regulatory submission to health agencies," said MEDIAN Chief Executive Officer Fredrik Brag.

Under terms of the agreement, Quintiles will have the potential to be awarded warrants, which if exercised could amount to up to a 15% equity position in the company.

Anne Pilling, Vice President, Quintiles Oncology Therapeutic Delivery Unit, said: "This partnership complements Quintiles' current portfolio of imaging solutions and provides further proof of our commitment to provide biopharma and healthcare service providers with the tools, expertise and services needed to increase productivity and better the lives of patients."

Images are essential in clinical trials and are used at all steps of cancer care, from patient diagnosis to monitoring. In clinical trials, they provide a critical indication of patient response to treatment of new candidate drug and are used as input for new drug and therapeutic schemes registration. MEDIAN's solution addresses two critical imaging challenges: data variability amongst readers and efficient management of the imaging data workflow.

About Quintiles: Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com

About MEDIAN Technologies: Based in Sophia Antipolis, MEDIAN was founded in 2002 by Fredrik Brag (Current CEO), Gérard Milhiet and Arnaud Butzbach. The company has a staff of 40, over half of whom work in R&D, and has a subsidiary in the USA.

MEDIAN Technologies offers solutions and services for diagnosing and monitoring cancer patients for clinical trials market in oncology, its priority market, and the patient care market. MEDIAN a collaborated with institutes at the cutting edge of medical imaging, among which the French National Institute for Computer Science and Control (INRIA), Chicago University and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL).

MEDIAN Technologies has been present in the market since 2007 through direct and indirect sales of its LMS solutions and alliances with specialist cancer centers in Europe and the USA.

For more information on MEDIAN, please visit: www.mediantechnologies.com

QUINTILES
Quintiles Media Relations
Jay Johnson
+1 919 993 2066
[email protected]
or
Quintiles Investor Relations
Greg Connors
+1 919 998 2000
[email protected]
or
MEDIAN
MEDIAN Technologies
Fredrik Brag, CEO
+33 492 906 582
[email protected]
or
Press
ALIZE RP
Caroline Carmagnol
+ 33 664 189 959
+ 33 142 688 643
[email protected]
Anne-Sophie Cosquéric
+ 33 1 42 68 86 41
[email protected]
or
Investors
ACTIFIN
Anaïs de Scitivaux
+ 33 1 56 88 11 14
[email protected]


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDIAN TECHNO
04/25 MEDIAN TECHNO : Technologies is awarded the 2017 Tech 40 Label and joins EnterNe..
04/25 MEDIAN TECHNOLOGIES : is Awarded the 2017 Tech 40 Label and Joins EnterNext Tech..
04/12 MEDIAN TECHNOLOGIES : Publication of the Annual Report for Financial Year 2016
04/12 MEDIAN TECHNOLOGIES : Reports Full Year 2016 Financial Results
04/06 MEDIAN TECHNOLOGIES : and inVentiv Health Announce Strategic Alliance to Provide..
02/28 MEDIAN TECHNOLOGIES : to Present at Cowen and Company 37th Annual Health Care Co..
02/14 MEDIAN TECHNOLOGIES : to Attend the Annual Meeting of the Asian Pacific Associat..
01/04 MEDIAN TECHNO : Yearly Median Technologies Liquidity Contract Statement Contract..
2016 MEDIAN TECHNO : Completion of a Reserved Share Capital Increase of Median Techno..
2016 MEDIAN TECHNO : Completion of a Reserved Share Capital Increase of Median Techno..
More news
Sector news : Software - NEC
04/28 Strongest week since December for European shares as investors pile in
04/28DJMICROSOFT : Makes Gains On the Cloud -- WSJ
04/28 Google parent Alphabet's profit up 29 percent on strong ad sales
04/28 INTEL : revenue misses estimates as data centre growth slows
04/27 Apple in talks to launch money-transfer service - Recode
More sector news : Software - NEC
Advertisement
Chart MEDIAN TECHNO
Duration : Period :
Median Techno Technical Analysis Chart | ALMDT | FR0011049824 | 4-Traders
Full-screen chart
Technical analysis trends MEDIAN TECHNO
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Managers
NameTitle
Fredrik Bjjorn Brag Chairman, CEO & Head-Investor Relations
Arnaud Butzbach Chief Technology Officer & VP-Operations
Bernard Reymann Chief Financial Officer
Souhil Zaïm Chief Medical Officer
Gerard Milhiet Director & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDIAN TECHNO17.73%163
MICROSOFT CORPORATION10.17%528 546
RED HAT INC26.37%15 659
HEXAGON AB15.76%15 079
CITRIX SYSTEMS, INC.13.82%12 237
SYNOPSYS, INC.25.21%11 092
More Results